Exclusive: Liquid-biopsy startup closes $17M to fund ovarian cancer diagnostic test
Liquid biopsy startup AOA Dx has collected $17 million to support the development of its diagnostic test for ovarian cancer as well as the platform on which it is based.
The company’s diagnostic platform, GlycoLocate, is designed to detect cell signaling molecules called gangliosides in the blood. Elevated levels are often seen in cancer patients.
In January, AOA Dx started its prospective study OVERT to investigate its first diagnostic test, AKRIVIS GD, for ovarian cancer. The trial is recruiting across 20 US sites such as hospitals, gynecology and oncology clinics, CEO Oriana Papin-Zoghb told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.